Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing arctigenin

A technology of arctigenin and composition, which is applied in the field of anticancer drug composition to achieve remarkable curative effect, reduce toxic and side effects, and improve compliance

Active Publication Date: 2015-05-13
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In this dosing regimen, irinotecan and cisplatin were not administered simultaneously in the form of a pharmaceutical composition, but were administered separately in sequence, and the initial effective rate was only 31.4%.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1 Pharmaceutical composition microemulsion preparation of the present invention

[0021] Arctigenin 0.001g Irinotecan Hydrochloride 10g peppermint 35g Polyoxyethylene-23-lauryl ether 60g 1,2-propanediol 30g

[0022] Preparation process: Weigh the prescription amount of peppermint oil, polyoxyethylene-23-lauryl ether, and 1,2-propylene glycol, mix and stir evenly, then add arctigenin and irinotecan hydrochloride to dissolve, and ultrasonic treatment can also be used to accelerate the dissolution , to obtain a clarified concentrate, which is arctigenin and irinotecan hydrochloride microemulsion concentrate. The particle size was measured by a laser particle size analyzer, and the average particle size was 15nm.

Embodiment 2

[0023] Embodiment 2 Microemulsion preparation of pharmaceutical composition of the present invention

[0024] Arctigenin 1g Irinotecan Hydrochloride 10g Hydrogenated Coco Glycerides 5g Lauroyl macrogol-32-glyceride 20g 1,2-propanediol 5g polyethylene glycol 3350 20g

[0025] Preparation process: Weigh the prescription amount of hydrogenated cocoglyceride, lauroyl polyethylene glycol-32-glyceride, 1,2-propylene glycol, polyethylene glycol 3350, mix and stir evenly, and then add arctigenin, iridine hydrochloride Rinotecan can be dissolved, and ultrasonic treatment can also be used to accelerate the dissolution to obtain a clear concentrated solution, which is arctigenin and irinotecan hydrochloride microemulsion concentrate. The particle size was measured by a laser particle size analyzer, and the average particle size was 40nm.

Embodiment 3

[0026] Embodiment 3 Microemulsion preparation of pharmaceutical composition of the present invention

[0027] Arctigenin 10g Irinotecan Hydrochloride 1g peppermint 35g Polyoxyethylene-23-lauryl ether 60g 1,2-propanediol 30g

[0028] The preparation process is the same as in Example 2. The particle size was measured by a laser particle size analyzer, and the average particle size was 36nm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of medicines, and in particular relates to a pharmaceutical composition containing arctigenin. The pharmaceutical composition also contains a DNA (deoxyribonucleic acid) topoisomerase I inhibitor. The invention provides a micro-emulsion preparation and injection containing the pharmaceutical composition. Compared with single medicines, the pharmaceutical composition provided by the invention has a synergetic effect in the aspect of inhibiting the non-small cell lung cancer.

Description

technical field [0001] The invention relates to an anticancer drug composition, in particular to an anticancer drug composition containing arctigenin and DNA topoisomerase I inhibitor. Background technique [0002] Non-small cell lung cancer is the most common pathological type of lung cancer, accounting for about 85% of lung cancers. Non-small cell lung cancer includes several types such as squamous cell carcinoma, adenocarcinoma and large cell carcinoma. The cancer cells of non-small cell carcinoma grow slowly, the degree of malignancy is relatively low, and the diffusion and metastasis occur later. The clinical treatment of non-small cell lung cancer mainly includes surgical treatment, radiotherapy, chemotherapy, traditional Chinese medicine treatment and new treatment methods represented by molecular targeted therapy, but the sensitivity of non-small cell lung cancer to chemotherapy and radiotherapy is poor. Effective treatment is an urgent problem in the current treatm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61K31/4745A61P35/00A61K31/365
Inventor 赵志全姚景春
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com